Press Release.
Martinsried/Munich, 29. April 2009. MediGene AG (Frankfurt: MDG, Prime Standard, TecDAX) announced today that Dr. Peter Heinrich, Chief Executive Officer, has resigned from his position as member of the Executive Board with immediate effect. The Supervisory Board has accepted the resignation with great regret.
” On behalf of the MediGene Supervisory Board, I would like to thank Dr Peter Heinrich for his long time and successful leadership as Chief Executive Officer of the company. As a co-founder, he essentially shaped the company from the beginning. Due to his entrepreneurial achievements, MediGene today is an internationally acknowledged biotech company with subsidiaries in the UK and the USA and is listed in the German stock index TecDAX. The supervisory Board expresses its heartfelt thankfulness for his achievements and wishes him all the best for his future path of life”
says Prof Dr Ernst-Ludwig Winnacker, Chairman of the Supervisory Board of MediGene AG.
As successor, Dr. Frank Mathias has been appointed by the Supervisory Board. He has joined MediGene a year ago as Chief Operating Officer and Executive Board Member for Marketing, Sales and Business Development and has been responsible for the ongoing partnering process for the cancer drug candidate EndoTAG-1. The pharmacist with PhD has around 20 years’ experience in the pharma and biotech industry, among others as General Manager of Amgen GmbH, the German subsidiary of one of the world-leading biotechnology company Amgen Inc.
Dr. Mathias studied pharmacy at Paris VI University, taking his PhD in 1991. He embarked on his career in industry in 1988 as International Product Manager with Hoechst AG, Frankfurt, then in 1990 joined Albert-Roussel Pharma GmbH in Wiesbaden, first as a Pharmaceuticals Officer, then as a Product Group Manager and as Deputy Head of Marketing. In 1995 Dr. Mathias launched the Anti-Infectives Marketing Department at Hoechst Pharma in Frankfurt before moving as Head of Marketing to Servier Deutschland GmbH in Munich and taking over as General Manager there in 1996. In 2002 he moved as Head of Marketing to Amgen GmbH, Munich, the company he led successfully as General Manager since 2003. In April 2008, he joined the Executive Board of MediGene AG.
“I would like to express my thanks for the trust put in me by to the Supervisory Board. I accept the new challenge with great pleasure and a deep confidence that MediGene AG will continue to develop successfully. MediGene has an excellent team of employees and I look very much forward to working with them furthermore”
says Dr Frank Mathias, the new Chief Executive Officer of MediGene AG.
This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademark of MediGene AG. This trademark may be held or licensed for specific countries.
MediGene AG is a publicly listed (Frankfurt: MDG, Prime Standard, TecDAX) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies and has several drug candidates in clinical development, two of which provide significant sales potential. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.
Contact MediGene AG
E-mail: investor@medigene.com
Fax: +49 – 89 – 85 65 – 2920
Julia Hofmann / Dr. Nadja Wolf,
Public Relations,
Tel.: +49 – 89 – 85 65 – 3324
Dr. Georg Dönges,
Investor Relations,
Tel.: +49 – 89 – 85 65 – 2946
